Pharmafile Logo

Peter Impey

- PMLiVE

AZ and Inserm collaborate on diabetes and kidney disease

Three-year partnership will look at new therapeutic approaches

Allergan logo

More waiting for Allergan and Gedeon Richter’s antipsychotic

FDA announced it will take another three months to review cariprazine for schizophrenia

Teva Pharma logo

Teva drug shows promise in movement disorder

Deutetrabenazine could be the first US-approved drug for tardive dyskinesia 

- PMLiVE

GSK sets up new research initiative in Seattle

Will use an independent research base to understand how cells work

- PMLiVE

Novartis gets FDA nod for rare blood disorder drug

Promacta will provide a treatment option for children over 6 years old

- PMLiVE

GW Pharma appoints Julian Gangolli as North American president

Appointment coincides with GW Pharma’s US launch

- PMLiVE

Immodulon Therapeutics appointments two new board of directors

Anthony Bolton and Sir Simon Robertson join the biopharma firm

- PMLiVE

Novo Nordisk becomes diabetes drug sales leader

Supplants former frontrunner Sanofi - but both firms set for a tough 2015

- PMLiVE

AZ’s phase III gout data frustrates firm

Lesinurad discrepancies highlighted in clinical trials

- PMLiVE

FDA approves brain implant for Parkinson’s disease

The Brio Neurostimulation System also found to improve essential tremor

- PMLiVE

Former Sanofi UK MD to head Teva UK

Steve Oldfield has been named as the firm’s new general manager

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links